### RECEIVED CENTRAL FAX CENTER

AUG 0 1 2005



Vertex Pharmaceuticals Incorporated 130 Waverly Street • Cambridge, MA 02139-4242 Tel. 617.444.6100 • Fax 617.444.6483 http://www.vpharm.com

## **FAX TRANSMISSION**

| То                  | 571-273-8300        |  |  |  |  |
|---------------------|---------------------|--|--|--|--|
| Examiner            | Rebecca L. Anderson |  |  |  |  |
| Group Art Unit      | 1626                |  |  |  |  |
| From                | Karen E. Brown      |  |  |  |  |
| Date                | August 1, 2005      |  |  |  |  |
| Application No.     | 10/626,356          |  |  |  |  |
| Attorney Docket No. | VPI/00-122 DIV2 US  |  |  |  |  |
| Total Pages         | 9                   |  |  |  |  |

**Message or Comment** 

If any problems occur with this fax transmittal, please call (617) 444-6168 immediately.

# RECEIVED CENTRAL FAX CENTER

AUG 0 1 2005

Attorney Docket No.: VPI/00-122 DIV2 US

#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.:

10/626,356

Confirmation No.:

1551

Filing Date:

July 24, 2003

Examiner:

Rebecca L. Anderson

Group Art Unit:

1626

Applicants:

Michael R. Hale et al.

For:

ISOXAZOLE COMPOSITIONS USEFUL AS INHIBITORS

OF ERK

#### Certificate of Facsimile Transmission Under 37 CFR 1.8

I hereby certify that this correspondence and any documents referred to as attached hereto is/are being facsimile transmitted to the United States Patent and Trademark Office on August 1, 2005.

Signature Susan Batty-Gunn
Typed or Printed Name

August 1, 2005 Cambridge, Massachusetts

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

#### TRANSMITTAL LETTER

Sir:

Transmitted herewith: [X] a Reply to Office Action; [X] a Petition for Extension of Time; [] a substitute Specification; [] a Declaration; [] a Supplemental Declaration; [] a Power of Attorney; [] an Associate Power of Attorney; [] formal drawings; [] Notice of Appeal; [] Appeal Brief; [] Terminal Disclaimer; to be filed in the above-identified patent application.

Applicants:

Michael R. Hale et al.

Application No.:

10/626,356

#### FEE FOR ADDITIONAL CLAIMS

- [X] A fee for additional claims is not required.
- [] A fee for additional claims is required.

The additional fee has been calculated as shown below:

|   | CLAIMS<br>REMAININ<br>AFTER<br>AMENDME                |    | NU<br>PRI | SHEST<br>MBER<br>EVIOUS<br>ID FOR |       | PRESENT<br>EXTRA | RATE      |            | DDITIONAL<br>EES |
|---|---|----|-----------|-----------------------------------|-------|------------------|-----------|------------|------------------|
| TOTA  | AL CLAIMS   | 34 | -         | 34                                | * =   | x                | \$ 50     | = \$       | 0                |
| INDE  | PENDENT<br>MS   | 1  | <b>-</b>  | 3                                 | ** =  | x                | \$200     | = \$       | 0                |
| FIRST PRESENTATION OF A MULTIPLE DEPENDENT CLAIM + \$360 = \$ |   |    |           |                                   |       |                  |           |            |                  |
| **  | If less than 20, insert 20. If less than 3, insert 3. |    |           |                                   | TOTAL |                  | <u>\$</u> | <u>. o</u> |                  |

- [] A check in the amount of \$\_\_ in payment of the filing fee is transmitted herewith.
- [] Please charge \$\_\_\_ to Deposit Account No. 50-0725 in payment of the filing fee. A duplicate copy of this transmittal letter is transmitted herewith.
- [X] The Director is hereby authorized to charge payment of any additional filing fees required under 37 C.F.R. § 1.16, in connection with the paper(s) transmitted herewith, or credit any overpayment of same, to deposit Account No. 50-0725. A duplicate copy of this transmittal letter is transmitted herewith.

Applicants:

Michael R. Hale et al.

Application No.:

10/626,356

#### **EXTENSION FEE**

- [X] The following extension is applicable to the Response filed herewith; [] \$120.00 extension fee for response within first month pursuant to 37 C.F.R. § 1.136(a); [] \$450.00 extension fee for response within second month pursuant to 37 C.F.R. § 1.136(a); [] \$1,020.00 extension fee for response within third month pursuant to 37 C.F.R. § 1.136(a); [] \$1,590.00 extension fee for response within fourth month pursuant to 37 C.F.R. § 1.136(a); [X] \$2,160.00 within fifth month pursuant to 37 C.F.R. § 1.136(a).
- [] A check in the amount of [] \$120.00; [] \$450.00; [] \$1,020.00; [] \$1,590.00; [] \$2,160.00 in payment of the extension fee is transmitted herewith.
- [X] Please charge the extension fee in the amount of [] \$120.00; [] \$450.00; [] \$1,020.00; [] \$1,590.00; [X] \$2,160.00 to Deposit Account No. 50-0725. A duplicate copy of this transmittal letter is transmitted herewith.
- [X] The Director is hereby authorized to charge payment of any additional fees required under 37 C.F.R. § 1.17 in connection with the paper(s) transmitted herewith, or to credit any overpayment of same, to Deposit Account No. 50-0725. A duplicate copy of this transmittal letter is transmitted herewith.

#### MISCELLANEOUS FEES

| [] | Please charge \$ | to Deposit Account No. 50-0725 for | · · · · · · · · · · · · · · · · · · · |
|----|------------------|------------------------------------|---------------------------------------|
|----|------------------|------------------------------------|---------------------------------------|

Respectfully submitted,

Karen E. Brown, Reg. No. 43,866 Attorney/Agent for Applicants

c/o Vertex Pharmaceuticals Incorporated
130 Waverly Street

Cambridge, Massachusetts 02139

Tel: (617) 444-6168 Fax: (617) 444-6483